ArticlemAbs
Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
- A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies.Scientific reports · 2026Article
- High-throughput strategies for monoclonal antibody screening: advances and challenges.Journal of biological engineering · 2025Review
- High-throughput specificity profiling of antibody libraries using ribosome display and microfluidics.Cell reports methods · 2024Article
- Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1.Antibodies (Basel, Switzerland) · 2024Article
- Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.Frontiers in immunology · 2024Review
- T-independent responses to polysaccharides in humans mobilize marginal zone B cells prediversified against gut bacterial antigens.Science immunology · 2023Article
- GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Article
- Antibody repertoire sequencing analysis.Acta biochimica et biophysica Sinica · 2022Review
- IL-10 revisited in systemic lupus erythematosus.Frontiers in immunology · 2022Review
- Protein Engineering: Advances in Phage Display for Basic Science and Medical Research.Biochemistry. Biokhimiia · 2022Review
- Generation of recombinant hyperimmune globulins from diverse B-cell repertoires.Nature biotechnology · 2021Article
- Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues.Science (New York, N.Y.) · 2021Article
- Hybridoma technology: is it still useful?Current research in immunology · 2021Review
- Potential Applications of Fluorescence-Activated Cell Sorting (FACS) and Droplet-Based Microfluidics in Promoting the Discovery of Specific Antibodies for Characterizations of Fish Immune Cells.Frontiers in immunology · 2021Review
- Antigen discovery tools for adaptive immune receptor repertoire research.Current opinion in systems biology · 2020Article
- Liquid drop of DNA libraries reveals total genome information.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Exhaustive Search of the Receptor Ligands by the CyCLOPS (Cytometry Cell-Labeling Operable Phage Screening) Technique.International journal of molecular sciences · 2020Article
- Rapid isolation of antigen-specific B-cells using droplet microfluidics.RSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Affinity-matured, functional anti-pathogen antibodies are present at low frequencies in natural human repertoires. These antibodies are often excellent candidates for therapeutic monoclonal antibodies. However, mining natural human antibody repertoires is a challenge. In this study, we demonstrate a new method that uses microfluidics, yeast display, and deep sequencing to identify 247 natively paired anti-pathogen single-chain variable fragments (scFvs), which were initially as rare as 1 in 100,000 in the human repertoires. Influenza A vaccination increased the frequency of influenza A antigen-binding scFv within the peripheral B cell repertoire from <0.1% in non-vaccinated donors to 0.3-0.4% in vaccinated donors, whereas pneumococcus vaccination did not increase the frequency of antigen-binding scFv. However, the pneumococcus scFv binders from the vaccinated library had higher heavy and light chain Replacement/Silent mutation (R/S) ratios, a measure of affinity maturation, than the pneumococcus binders from the corresponding non-vaccinated library. Thus, pneumococcus vaccination may increase the frequency of affinity-matured antibodies in human repertoires. We synthesized 10 anti-influenza A and nine anti-pneumococcus full-length antibodies that were highly abundant among antigen-binding scFv. All 10 anti-influenza A antibodies bound the appropriate antigen at K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.